Dr. Pressman is Professor and Chairman of the S. Mark Taper Foundation Imaging Center and Department, and Chief of the Section of Neuroradiology and Head and Neck Radiology at Cedars-Sinai Medical Center, located in Los Angeles, Ca.
Dr. Pressman is a past President of The American College of Radiology, the Western Neuroradiological Society, as well as past President of the California Radiological Society. Currently he is a member of the American Society of Neuroradiology and the American Society of Pediatric Neuroradiology.
Dr. Pressman earned his medical degree Cum Laude from Harvard Medical School after graduating Summa Cum Laude from Dartmouth College. After a surgical internship at Harvard's Peter Bent Brigham Hospital in Boston, he completed a diagnostic radiology residency at Columbia-Presbyterian Medical Center in New York and a Neuroradiology fellowship at George Washington University Hospital. During this period, he wrote many original papers for Computer Tomography(CT).
"I am delighted to be appointed to Chair the newly formed Medical Advisory Board (MAB) for AMI. I anticipate rapid expansion of our MAB, initially focusing on the potential for the Company's brachytherapy products," said Pressman.
James C. Katzaroff, CEO of AMI, stated, "It is with great pleasure I welcome Dr. Pressman's guidance in assisting the Company to enter the commercial marketplace with its therapeutic products. As AMI expands beyond the distribution and the production of stable and diagnostic radioisotopes, to the manufacturing of therapeutic products with AMI's own product line, Dr. Pressman will be instrumental in providing a nationally-recognized practitioner's perspective and expertise that will enable the company to meet the growing needs of a dynamic nuclear medicine marketplace."
Dr. Fisher is known internationally for his expertise in the dosimetry and effects of radioactive materials, including medically administered radiopharmaceuticals for diagnostic and therapeutic benefit.
Dr. Fisher is a recent president of the Health Physics Society, an international organization of professionals engaged in the science and practice of radiation safety. He also serves on the Medical Internal Radiation Dose Committee of the Society of Nuclear Medicine and Molecular Imaging, which develops standard methods for radiopharmaceutical dosimetry.
Dr. Fisher previously served on the U.S. Nuclear Regulatory Commission's Advisory Committee on the Medical Uses of Isotopes. He recently completed a 35-year career at the Pacific Northwest National Laboratory (PNNL) and holds seven patents, including patents licensed by AMI for its brachytherapy products.
Dr. Alan E. Waltar serves as Chair of the Scientific Committee for AMI, having recently retired as Director of Nuclear Energy at the Pacific Northwest National Laboratory (PNNL). He has also served as Head of the Nuclear Engineering Department for Texas A&M and President of the American Nuclear Society.
He holds a PhD in Engineering Science from the UC, Berkeley. Dr. Waltar served in numerous engineering and management roles in his 30-year career with Westinghouse Hanford Company. He was instrumental in the formation of the World Nuclear University (WNU) Summer Institute (SI) and has served as a mentor, lecturer, and MC for all six of the SIs to date—as well as the WNU Radioisotopes School in Korea (2010). Additionally, he led a People-to-People Ambassadors Nuclear Delegation to China in October 2007 and India in 2009.
Dr. Waltar currently serves as a consultant to numerous governmental national and international nuclear organizations as well as several private nuclear firms. His support for AMI is focused on helping the company meet their goals of efficient, broad spectrum, domestic radioisotope production.
Dr. Ludwig E. Feinendegen is a medical doctor known for his pioneering work and leadership in the fields of both diagnostic and therapeutic applications of radionuclides through various roles and research in nuclear medicine, internal medicine, cell biology and radiobiology. Dr. Feinendegen has numerous honors from national and international affiliations and has authored over 700 publications in molecular nuclear medicine, cell biology and low-dose radiobiology.
He earned his MD at the University Medical School Cologne, Germany, MD and trained in internal medicine, radiology and surgery in both Germany and USA. Dr Feinendegen has conducted research at leading institutions including Brookhaven National Laboratory (BNL) in New York, EURATOM in Brussels, Belgium, and the Institute du Radium in Paris, France. Dr. Feinendegen was a Full Professor and Director for the Department of Nuclear Medicine at Heinrich-Heine University (HHU) in Duesseldorf, Germany and the Director of the Institute of Medicine at the Research Center Juelich, Germany for over 25 years. He then returned to the United States working at BNL as a Senior Scientist, then at the US Department of Energy as a Program Manager, followed by a position as a Fogarty Scholar at the National Institutes of Health. He is currently a Professor emeritus at HHU and a Guest Scientist at BNL.
Dr. Ludwig E. Feinendegen‘s focus on the AMI Medical Advisory Board is the clinical introduction of AMIC’s yttrium-90 brachytherapy products and European markets.
Dr. Albert S. DeNittis is currently is the Chief of Radiation Oncology at Lankenau Medical Center and Clinical Professor at Lankenau Insitute for Medical Research in Wynnewood, Pennsylvania and
the Director of Radiation Oncology at Brodesseur Cancer Center in New Jersey. He is also the Principal Investigator and in charge of a grant awarded by the NIH for its National Cancer Oncology
Research Program (NCORP) at Main Line Health. Dr. DeNittis practice experience includes image-guided radiosurgery, stereotactic body radiation therapy (SBRT), intensity modulated radiation
therapy (IMRT), image guided radiation therapy (IGRT), high-dose rate (HDR) brachytherapy, cranial and extracranial stereotactic radiosurgery, respiratory gating, and Cyberknife.
Dr. DeNittis has served on numerous regional, national and government committees related to key issues in the field of oncology including the NRG Oncology group which focuses on protocol development for cancer patients on the national level. He has received regional and national awards for his research and his clinical work and authored over 100 publications and presentations as well as 6 book chapters. He has. Dr. DeNittis previously has been awarded a number of grants to study the impact of various novel oncology drugs and radiation protocols. He is a long standing member of key professional societies including the American Society of Radiation Oncology, the American Society of Clinical Oncology, and American Brachytherapy Society. Dr. DeNittis is a cofounder and board member of DermRad Therapy which is developing a multidisciplinary approach to skin cancer treatment.
Dr. DeNittis earned a BA and a MS at Rutgers University and a MD from the Robert Wood Johnson Medical School at the University of Medicine and Dentistry of New Jersey. He completed postdoctoral training internships and residency at the Department of Radiation Oncology at the Hospital of the University of Pennsylvania. Dr. DeNittis is board certified by the American Board of Radiology and Licensed in New Jersey and Pennsylvania.
Dr. Alice Villalobos is a well known pioneer in the field of cancer care for companion animals and a founding member of the Veterinary Cancer Society. A 1972 graduate of UC Davis, she completed Dr. Gordon Theilen’s first mock residency program in oncology and has served the profession by consulting, writing and lecturing in the rapidly growing field of veterinary oncology and end of life care.
Dr. Alice Villalobos is President Emeritus of the Society for Veterinary Medical Ethics, Past President of the American Association of Human Animal Bond Veterinarians and Chair of the Veterinary Academy for the National Academies of Practice. She operated Coast Pet Clinic/Animal Cancer Center for 25 years, which is now VCA Coast Animal Hospital. She is the author of numerous articles, papers, and including her classic veterinarian textbook, Canine and Feline Geriatric Oncology: Honoring the Human-Animal Bond. She has lectured worldwide on oncology, quality of life, the human-animal bond and end of life care and bioethics. She founded Pawspice, an end of life care program that embraces kinder, gentler palliative cancer medicine and integrative care for pets with cancer and terminal illness (www.Pawspice.com). Dr. Alice is Director of Animal Oncology Consultation Service in Woodland Hill, California and Pawspice at VCA Coast Animal Hospital in Hermosa Beach, California. Dr. Alice was elected 2016 Hermosa Beach Woman of the Year.
Dr. Alice’s role with AMIC is to support the commercialization of the Company’s yttrium-90 brachytherapy products for use in companion animals.